1-氮杂双环[3.2.1]辛烷-5-甲醛 | 141593-56-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 中文名称: 1-氮杂双环[3.2.1]辛烷-5-甲醛
• 英文名称: (+/-) 1-Azabicyclo[3.2.1]oct-5-ylcarboxaldehyde
• 英文别名: 5-carboxaldehyde-1-azabicyclo[3.2.1]octane；1-aza-bicyclo[3.2.1]octane-5-carbaldehyde；1-azabicyclo[3.2.1]oct-5-ylcarboxaldehyde；1-Azabicyclo[3.2.1]octane-5-carboxaldehyde；1-azabicyclo[3.2.1]octane-5-carbaldehyde
• CAS: 141593-56-8
• 化学式: C₈H₁₃NO
• 分子量: 139.197
• InChiKey: AZBLBPGNJYNYEC-UHFFFAOYSA-N

物化性质

• 沸点：
  199.7±23.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-氮杂双环[3.2.1]辛烷-5-甲醛 在 正丁基锂 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 5-乙炔基-1-氮杂双环[3.2.1]辛烷
  参考文献：
  名称：

  Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands

  摘要：

  The effect of variation of the 1-azabicyclic substituent on the novel 1,2,3-triazol-4-yl-, 1,2,4-triazol-1-yl-, tetrazol-5-yl-, and tetrazol-2-yl-based muscarinic receptor ligands ha, been studied, and the exo-azabicyclic[2.2.1]hept-3-yl substituent was found to give the most potent and efficacious compounds. In addition, variation of the second substituent on 1,2,4-triazol-1-yl- and tetrazol-2-yl-based muscarinic receptor ligands has yielded a series of novel compounds with high potencies and efficacies, ranging from full agonists to antagonists. Small lipophilic electron withdrawing substituents give potent but low efficacy compounds, while small polar electron donating substituents give potent and efficacious compounds. The activity of these compounds is described in terms of a model of the receptor involving lipophilic and hydrogen bonding interactions. These compounds provide muscarinic ligands with high potency and a range of efficacies suitable for testing as candidate drugs in the treatment of Alzheimer's disease.

  DOI：

  10.1021/jm00091a007
• 作为产物：
  描述：

  1-氮杂双环[3.2.1]辛烷-5-羧酸 在 吡啶 、 氯化亚砜 、 二异丁基氢化铝 作用下， 以 四氢呋喃 、 氯仿 、 甲苯 为溶剂， 反应 4.75h， 生成 1-氮杂双环[3.2.1]辛烷-5-甲醛
  参考文献：
  名称：

  Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands

  摘要：

  The effect of variation of the 1-azabicyclic substituent on the novel 1,2,3-triazol-4-yl-, 1,2,4-triazol-1-yl-, tetrazol-5-yl-, and tetrazol-2-yl-based muscarinic receptor ligands ha, been studied, and the exo-azabicyclic[2.2.1]hept-3-yl substituent was found to give the most potent and efficacious compounds. In addition, variation of the second substituent on 1,2,4-triazol-1-yl- and tetrazol-2-yl-based muscarinic receptor ligands has yielded a series of novel compounds with high potencies and efficacies, ranging from full agonists to antagonists. Small lipophilic electron withdrawing substituents give potent but low efficacy compounds, while small polar electron donating substituents give potent and efficacious compounds. The activity of these compounds is described in terms of a model of the receptor involving lipophilic and hydrogen bonding interactions. These compounds provide muscarinic ligands with high potency and a range of efficacies suitable for testing as candidate drugs in the treatment of Alzheimer's disease.

  DOI：

  10.1021/jm00091a007
• 作为试剂：
  描述：

  1-azabicyclo[3.2.1]octan-5-methanol 、 戴斯-马丁氧化剂 在 二氯甲烷 、 1-氮杂双环[3.2.1]辛烷-5-甲醛 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以to give the desired compound 1-aza-bicyclo[3.2.1]octane-5-carbaldehyde which的产率得到1-氮杂双环[3.2.1]辛烷-5-甲醛
  参考文献：
  名称：

  NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

  摘要：

  化合物的结构如公式（I）所示：其中变量Y，R1，R2，R3，R4和R5的定义如下。本文所描述的化合物是聚（ADP核糖）聚合酶活性的抑制剂。本文还描述了包括至少一种本文所描述的化合物的药物组合物，以及使用这些化合物和药物组合物治疗通过抑制PARP活性改善的疾病，障碍和状况。

  公开号：

  US20090062268A1

文献信息

• Method of treating gastrointestinal motility disorders
  申请人：Novo Nordisk A/S

  公开号：US06265419B1

  公开（公告）日：2001-07-24

  The present invention relates to a novel method for treating a mammal suffering from gastrointestinal motility disorders.

  这项发明涉及一种治疗患有胃肠动力障碍的哺乳动物的新方法。
• Method of treating urinary bladder dysfunctions
  申请人：Novo Nordisk A/S

  公开号：US05612351A1

  公开（公告）日：1997-03-18

  The present invention relates to a novel method for treating a mammal suffering from urinary bladder dysfunctions.

  这项发明涉及一种治疗患有尿道膀胱功能障碍的哺乳动物的新方法。
• Certain 3-(1,2,5-oxa- or thiadiazol-4-yl)-1-azabicyclo [2.2.2]octanes
  申请人：Novo Nordisk A/S

  公开号：US05260314A1

  公开（公告）日：1993-11-09

  The present invention relates to therapeutically active piperidine compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.

  本发明涉及治疗活性吡啶化合物，一种制备该化合物的方法以及包含该化合物的药物组合物。这些新颖的化合物可用作刺激哺乳动物前脑和海马的认知功能的兴奋剂，特别适用于治疗阿尔茨海默病、严重疼痛症状和青光眼。
• Heterocyclic compounds and their preparation and use
  申请人：Novo Nordisk A/S

  公开号：US05527813A1

  公开（公告）日：1996-06-18

  The present invention relates to therapeutically active azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.

  本发明涉及治疗活性的杂环化合物，一种制备该化合物的方法以及包含该化合物的药物组合物。这些新颖的化合物可用作哺乳动物前脑和海马的认知功能刺激剂，特别适用于治疗阿尔茨海默病、严重疼痛症状和青光眼。
• Novel compounds
  申请人：BEECHAM GROUP PLC

  公开号：EP0338723A1

  公开（公告）日：1989-10-25

  Novel compounds of formula (I), a process for their preparation, and their use as pharmaceutical agents are described: wherein R₁ represents in which each of p and q independently represents an integer of 2 to 4, r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1; R₂ is a group OR₄, where R₄ is C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, a group OCOR₅ where R₅ is hydrogen or R₄, or a group NHR₆ or NR₇R₈ where R₆, R₇ and R₈ are independently C₁₋₂ alkyl; and R₃ is hydrogen or C₁₋₄ alkyl, subject to the proviso that when R₂ is a group OCOR₅ or a group NHR₆, R₃ is C₁₋₄ alkyl.

  本研究描述了式 (I) 的新型化合物、其制备方法及其作为药剂的用途： 其中 R₁ 代表 其中 p 和 q 各自独立地代表 2 至 4 的整数，r 代表 2 至 4 的整数，s 代表 1 或 2，t 代表 0 或 1； R₂ 是基团 OR₄，其中 R₄ 是 C₁₋₄ 烷基、C₂₋₄ 烯基、C₂₋₄ 烷炔基、基团 OCOR₅（其中 R₅ 是氢或 R₄）或基团 NHR₆ 或 NR₇（其中 R₆、R₇ 和 R₈ 独立地是 C₁₋₂ 烷基）；以及 R₃ 是氢或 C₁₋₄ 烷基，但当 R₂ 是基团 OCOR₅ 或基团 NHR₆ 时，R₃ 是 C₁₋₄ 烷基。